Get the Stockscreener App
252.89
2.41%
5.96
After Hours:
252.89
Penumbra Inc stock is traded at $252.89, with a volume of 444.43K.
It is up +2.41% in the last 24 hours and up +2.99% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
See More
Previous Close:
$246.93
Open:
$248.32
24h Volume:
444.43K
Relative Volume:
1.26
Market Cap:
$9.71B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
294.06
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
+0.26%
1M Performance:
+2.99%
6M Performance:
+32.52%
1Y Performance:
-2.13%
1-Day Range:
$245.27
$254.00
1-Week Range:
$237.65
$258.52
52-Week Range:
$148.00
$277.34
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
252.89 | 9.71B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
113.02 | 196.03B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.65 | 140.97B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
362.80 | 138.31B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
85.25 | 109.31B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.04 | 41.90B | 6.60B | 4.16B | 490.10M | 6.93 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Aneurysm Coiling and Embolization Devices Market to Grow by USD 2.0 Billion from 2025-2029, Driven by Rising IAS Cases and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? - MSN
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Penumbra stock rises following Stryker's Inari Medical acquisition By Investing.com - Investing.com South Africa
Penumbra stock rises following Stryker's Inari Medical acquisition - Investing.com India
Penumbra stock rises following Stryker’s Inari Medical acquisition By Investing.com - Investing.com Nigeria
Penumbra spikes after Stryker- Inari deal - MSN
Penumbra (NYSE:PEN) Trading 7.1% HigherStill a Buy? - MarketBeat
Insider Sell: Harpreet Grewal Sells Shares of Penumbra Inc (PEN) - GuruFocus.com
Penumbra stock gains after Stryker- Inari deal (NARI:NASDAQ) - Seeking Alpha
Penumbra: Re-Rated For The Wrong Reasons (NYSE:PEN) - Seeking Alpha
Reasons to Add Penumbra Stock to Your Portfolio Now - MSN
Insider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 167 Shares of Stock - MarketBeat
Penumbra (NYSE:PEN) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Capital Allocation Trends At Penumbra (NYSE:PEN) Aren't Ideal - Yahoo Finance
Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects - Simply Wall St
Penumbra to Present at J.P. Morgan Healthcare Conference 2025: Key Investor Event Ahead - StockTitan
Penumbra Inc.: An Insight Into Its Margin Expansion Opportunities & Other Major Drivers - Smartkarma
Penumbra, Inc. (NYSE:PEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
Principal Financial Group Inc. Has $17.62 Million Holdings in Penumbra, Inc. (NYSE:PEN) - MarketBeat
(PEN)Analyzing Penumbra's Short Interest - Benzinga
Penumbra, Inc. (NYSE:PEN) CEO Adam Elsesser Sells 15,000 Shares - MarketBeat
Penumbra CEO Adam Elsesser sells $3.64 million in stock By Investing.com - Investing.com Australia
Penumbra CEO Adam Elsesser sells $3.64 million in stock - Investing.com India
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
Penumbra, Inc. (NYSE:PEN) Shares Purchased by Barclays PLC - MarketBeat
Penumbra Launches Lightning Flash 2.0Latest CAVT Technology D - GuruFocus.com
Penumbra price target raised to $285 from $240 at Truist - Yahoo Finance
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy TechnologiesLightning Flash™ 2.0 and Lightning Bolt™ 7in Europe - The Eastern Progress Online
Y Intercept Hong Kong Ltd Cuts Holdings in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Interventional Neurology Market Is Booming Worldwide - openPR
Penumbra's SWOT analysis: innovation drives growth amid market challenges - Investing.com India
Penumbra's SWOT analysis: innovation drives growth amid market challenges By Investing.com - Investing.com Canada
Penumbra (NYSE:PEN) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Geode Capital Management LLC Purchases 11,257 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst - Benzinga
Oppenheimer Initiates Coverage on Penumbra (NYSE:PEN) - MarketBeat
Oppenheimer Initiates Coverage of Penumbra (PEN) with Outperform Recommendation - Nasdaq
Franklin Resources Inc. Increases Stake in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Wilmington Savings Fund Society FSB Makes New $7 Million Investment in Penumbra, Inc. (NYSE:PEN) - MarketBeat
State Street Corp Purchases 3,863 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
BNP Paribas Financial Markets Lowers Stake in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):